These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 11395637)

  • 1. Polyclonal Antibodies Against gp185HER2 Peptides: Their Putative Role in the Identification of a Particular HER2 Status in Patients With Breast Cancer.
    Di Modugno F; Buglioni S; Mottolese M; Del Bello D; Cascioli S; Chersi A; Santoni A; Nisticò P
    J Immunother (1991); 2001 May; 24(3):221-231. PubMed ID: 11395637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polyclonal antibodies against gp185HER2 peptides: their putative role in the identification of a particular HER2 status in patients with breast cancer.
    Di Modugno F; Buglioni S; Mottolese M; Bello DD; Cascioli S; Chersi A; Santoni A; Nisticò P
    J Immunother; 2001; 24(3):221-31. PubMed ID: 11394499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
    Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
    Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue.
    Shi Y; Huang W; Tan Y; Jin X; Dua R; Penuel E; Mukherjee A; Sperinde J; Pannu H; Chenna A; DeFazio-Eli L; Pidaparthi S; Badal Y; Wallweber G; Chen L; Williams S; Tahir H; Larson J; Goodman L; Whitcomb J; Petropoulos C; Winslow J
    Diagn Mol Pathol; 2009 Mar; 18(1):11-21. PubMed ID: 19214113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process.
    Vincent-Salomon A; Jouve M; Genin P; Fréneaux P; Sigal-Zafrani B; Caly M; Beuzeboc P; Pouillart P; Sastre-Garau X
    Cancer; 2002 Apr; 94(8):2169-73. PubMed ID: 12001113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients.
    Jaramillo A; Narayanan K; Campbell LG; Benshoff ND; Lybarger L; Hansen TH; Fleming TP; Dietz JR; Mohanakumar T
    Breast Cancer Res Treat; 2004 Nov; 88(1):29-41. PubMed ID: 15538043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases.
    Wei Q; Sheng L; Shui Y; Hu Q; Nordgren H; Carlsson J
    Ann Surg Oncol; 2008 Apr; 15(4):1193-201. PubMed ID: 18172732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
    Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
    Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response of established human breast tumors to vaccination with mammaglobin-A cDNA.
    Narayanan K; Jaramillo A; Benshoff ND; Campbell LG; Fleming TP; Dietz JR; Mohanakumar T
    J Natl Cancer Inst; 2004 Sep; 96(18):1388-96. PubMed ID: 15367572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer.
    Cabioglu N; Yazici MS; Arun B; Broglio KR; Hortobagyi GN; Price JE; Sahin A
    Clin Cancer Res; 2005 Aug; 11(16):5686-93. PubMed ID: 16115904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
    Peoples GE; Holmes JP; Hueman MT; Mittendorf EA; Amin A; Khoo S; Dehqanzada ZA; Gurney JM; Woll MM; Ryan GB; Storrer CE; Craig D; Ioannides CG; Ponniah S
    Clin Cancer Res; 2008 Feb; 14(3):797-803. PubMed ID: 18245541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer.
    Vazquez-Martin A; Colomer R; Menendez JA
    Eur J Cancer; 2007 May; 43(7):1117-24. PubMed ID: 17379503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies and vaccines--hope or illusion?
    Jäger D; Knuth A
    Breast; 2005 Dec; 14(6):631-5. PubMed ID: 16242931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth.
    Takai N; Jain A; Kawamata N; Popoviciu LM; Said JW; Whittaker S; Miyakawa I; Agus DB; Koeffler HP
    Cancer; 2005 Dec; 104(12):2701-8. PubMed ID: 16265675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of early placenta insulin-like growth factor in breast cancer cells provides an autocrine loop that predominantly enhances invasiveness and motility.
    Brandt B; Kemming D; Packeisen J; Simon R; Helms M; Feldmann U; Matuschek A; Kersting C; Hinrichs B; Bidart JM; Bellet D; Bartkowiak K; Dankbar N; Dittmar T; Sauter G; Boecker W; Buerger H
    Endocr Relat Cancer; 2005 Dec; 12(4):823-37. PubMed ID: 16322324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic and therapeutic role of HER2 in cancer.
    Ménard S; Pupa SM; Campiglio M; Tagliabue E
    Oncogene; 2003 Sep; 22(42):6570-8. PubMed ID: 14528282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine.
    Hueman MT; Stojadinovic A; Storrer CE; Foley RJ; Gurney JM; Shriver CD; Ponniah S; Peoples GE
    Breast Cancer Res Treat; 2006 Jul; 98(1):17-29. PubMed ID: 16758122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer.
    Woll MM; Hueman MT; Ryan GB; Ioannides CG; Henderson CG; Sesterhan IA; Shrivasta S; McLeod DG; Moul JW; Peoples GE
    Int J Oncol; 2004 Dec; 25(6):1769-80. PubMed ID: 15547716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
    Rydén L; Jirström K; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Thorstenson S; Jönsson PE; Landberg G
    J Clin Oncol; 2005 Jul; 23(21):4695-704. PubMed ID: 16034044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.